![]() |
|
|
Vol. 298, Issue 3, 1199-1205, September 2001
Department of Pharmaceutical Chemistry, The University of Kansas,
Lawrence, Kansas
The purpose of this work was to determine whether the in vitro
bronchiolar epithelial cell model, Calu-3, possesses efflux pump
activity by the multidrug resistance-associated protein-1 (MRP1).
Reverse transcription-polymerase chain reaction demonstrated MRP1 gene expression in Calu-3 cells. Indirect
fluorescence studies showed a basolateral membrane localization of MRP1
compared with P-glycoprotein (Pgp) that was found on the apical side of
these cells. An increase in the rate of accumulation of the MRP1
substrate calcein was observed following treatment with the organic
anion/MRP1 inhibitor indomethacin, the Pgp inhibitors cyclosporin A
(CsA) and vinblastine, as well as conditions of energy depletion. Total calcein efflux was significantly decreased with the MRP1 inhibitors probenecid and indomethacin, while total efflux was unchanged following
treatment with CsA. In the latter case, however, intracellular calcein
levels postefflux were significantly greater. Probenecid and
indomethacin increased calcein net secretion 2.4- and 3.5-fold, respectively. The efflux of etoposide, a known substrate for both Pgp
and MRP1, was shown to be mainly Pgp-mediated by using the multidrug-resistant inhibitors quinidine (mixed Pgp/MRP1), CsA (Pgp),
and MK571 (MRP1). Together, these data suggest that Calu-3 cells
possess MRP1 functional activity that is subordinate to Pgp efflux. We
present here kinetic analysis of calcein efflux from Calu-3 cells to
support our findings.
This article has been cited by other articles:
![]() |
J. Brillault, W. V. De Castro, T. Harnois, A. Kitzis, J.-C. Olivier, and W. Couet P-Glycoprotein-Mediated Transport of Moxifloxacin in a Calu-3 Lung Epithelial Cell Model Antimicrob. Agents Chemother., April 1, 2009; 53(4): 1457 - 1462. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Dai, Y. Chen, and W. F. Elmquist Distribution of the Novel Antifolate Pemetrexed to the Brain J. Pharmacol. Exp. Ther., October 1, 2005; 315(1): 222 - 229. [Abstract] [Full Text] [PDF] |
||||